Delving into the Latest Updates on Alaxia SAS with Synapse

Overview

This study aims to evaluate the analgesic effect and the safety of 4 doses of STR-324 administered as an infusion, with or without initial bolus, to patients suffering from post-operative pain.
The sensitivity of the pain model used in the trial will be evaluated with a standard group treated with morphine under the usual care conditions.

Start Date01 Dec 2020

Sponsor / Collaborator

Alaxia SAS

NCT02598999

/ TerminatedPhase 1

Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients

This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of a single ascending doses (SAD) and multiple ascending doses (MAD) of Hypothiocyanite (OSCN-), bovine lactoferrin (bLF) and their combination (ALX-009) in healthy male volunteers and patients suffering from cystic fibrosis (CF) and non-CF bronchiectasis (NCFBE).

Start Date01 Nov 2015

Sponsor / Collaborator

Alaxia SAS

100 Clinical Results associated with Alaxia SAS

Login to view more data

0 Patents (Medical) associated with Alaxia SAS

Login to view more data

100 Deals associated with Alaxia SAS

Login to view more data

100 Translational Medicine associated with Alaxia SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data